Vertex Pharmaceuticals (VRTX) Research & Development (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Research & Development of $961.6 million for Q1 2026, down 1.85% year-over-year from $979.7 million in Q1 2025, and down 1.24% quarter-over-quarter from $973.7 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Research & Development (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Research & Development history runs 18 years deep, the most recent figure standing at $961.6 million for Q1 2026.
- In Q1 2026, Research & Development fell 1.85% year-over-year to $961.6 million; the TTM figure through Mar 2026 stood at $3.9 billion (up 1.85% YoY), while the FY2025 annual figure was $3.9 billion, up 7.69% from the prior year.
- Research & Development for Q1 2026 stood at $961.6 million, down from $973.7 million in the prior quarter.
- The five-year high for Research & Development was $998.7 million in Q4 2024, with the low at $600.1 million in Q2 2022.
- The 5-year median for Research & Development is $824.6 million (2023), against an average of $835.6 million.
- The sharpest annual moves came in 2022 and 2025: Research & Development surged 38.12% in 2022, then retreated 2.5% in 2025.
- Vertex Pharmaceuticals' Research & Development stood at $694.1 million in 2022, then advanced by 18.8% to $824.6 million in 2023, then rose by 21.11% to $998.7 million in 2024, then slipped by 2.5% to $973.7 million in 2025, then dropped by 1.24% to $961.6 million in 2026.
- Business Quant data shows VRTX's Research & Development at $961.6 million in Q1 2026, $973.7 million in Q4 2025, and $977.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 202.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 993.80 Mn |
| Mar 31, 2026 | 961.60 Mn |
| Dec 31, 2025 | 973.70 Mn |
| Sep 30, 2025 | 977.70 Mn |
| Jun 30, 2025 | 978.40 Mn |
| Mar 31, 2025 | 979.70 Mn |
| Dec 31, 2024 | 998.70 Mn |
| Sep 30, 2024 | 875.90 Mn |
| Jun 30, 2024 | 966.60 Mn |
| Mar 31, 2024 | 789.10 Mn |
| Dec 31, 2023 | 824.60 Mn |
| Sep 30, 2023 | 810.00 Mn |
| Jun 30, 2023 | 785.70 Mn |
| Mar 31, 2023 | 742.60 Mn |
| Dec 31, 2022 | 694.10 Mn |
| Sep 30, 2022 | 645.00 Mn |
| Jun 30, 2022 | 600.10 Mn |
| Mar 31, 2022 | 601.10 Mn |
| Dec 31, 2021 | 567.80 Mn |
| Sep 30, 2021 | 467.00 Mn |